Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
clonazepam + propranolol
- Development stage
- Unknown
- Lead developer
- Med Manor Organics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Calmbeta is a fixed-dose combination of the benzodiazepine clonazepam and the non-selective beta-adrenergic receptor antagonist propranolol. Developed and marketed by Med Manor Organics, it is primarily indicated for the treatment of anxiety disorders, panic disorder, and associated physical symptoms such as palpitations, tremors, and tachycardia. Clonazepam acts as a positive allosteric modulator of the gamma-aminobutyric acid type A (GABA-A) receptor, enhancing inhibitory GABAergic neurotransmission in the central nervous system to alleviate emotional distress and prevent seizures. Propranolol competitively blocks beta-1 and beta-2 adrenergic receptors, reducing heart rate, blood pressure, and peripheral manifestations of somatic anxiety. Calmbeta is administered orally in tablet form.
- Brand names
- Calm BetaCalmbetaCalmbeta 20Calmbeta20Calmbeta-20Calmbeta-10Calmbeta10Calmbeta 10
02
Targets
ADRB1 (β1)ADRB3 (β3)GABRR (GABA-A receptor subunit rho)ADRB2 (β2)
Beyond the preview
Go deeper on clonazepam + propranolol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on clonazepam + propranolol.